Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
82,244 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Sep 30, 2026 | AmeriHealth | Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-004 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Steroid-Eluting Sinus Stents and ImplantsPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-107 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Spinal OrthosesPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA05-030 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Sleep Disorder Testing and Positive Airway Pressure Therapy Services and SuppliesPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA07-058 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Remote Electrical Neuromodulation for MigrainesPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA05-071 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Psychiatric Collaborative Care Management (CoCM)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA00-052 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | PPO Network Rules for Provision of Specialty Services for Durable Medical Equipment and Laboratory, Radiology, and Physical Medicine and Rehabilitative ServicesPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA00-010 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Pharmacogenetics and Metabolite Monitoring for Using Azathioprine (AZA)/6-Mercaptopurine (6-MP) TherapyPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA06-014 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Peroral Endoscopic Myotomy (POEM) ProceduresPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-117 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Percutaneous Coronary Intervention, Coronary Angiography, and Arterial UltrasoundPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-113 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Pembrolizumab and berahyaluronidase alfa-pmph (KEYTRUDA QLEX)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-189 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Pembrolizumab (Keytruda)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-121 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Outpatient Physical Medicine and Rehabilitation Services- Physical Therapy (PT) and Occupational Therapy (OT)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA10-003 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Otoplasty or Non-Surgical External Ear MoldingPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-058 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Orthognathic SurgeryPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-083 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Ocrelizumab (Ocrevus) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-088 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Nusinersen (Spinraza)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-086 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Non-Spinal Osteogenic Stimulators (Electrical and Ultrasonic)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA05-018 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Nivolumab (Opdivo), Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-120 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Neuropsychological Testing for Neurologically Based ConditionsPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA07-038 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Musculoskeletal ServicesPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA00-047 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Multiple Surgery Payment ReductionPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-032 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Mogamulizumab-kpkc (Poteligeo)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-102 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Modifiers 26 (Professional Component) and TC (Technical Component)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA03-011 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Medicare Part B vs. Part D Crossover DrugsPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-007 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Medical NecessityPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA12-008 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Measurement of Serum Antibodies to and Measurement of Serum Levels of BiologicsPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA06-019 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Lumasiran (Oxlumo)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-131 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Laser Interstitial Thermal Therapy (LITT)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA07-034 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Lanreotide (Somatuline Depot)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-090 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Laboratory Services for Members Enrolled in Health Maintenance Organization (HMO) or Health Maintenance Organization Point-of-Service (HMO-POS) ProductsPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA00-030 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) InhibitorsPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-073 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | High-Technology Radiology ServicesPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA09-002 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Facility Reporting of Observation ServicesPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA00-040 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | eviCore Lab ManagementPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA06-034 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Endoscopic Submucosal Dissection (ESD)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-118 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Durvalumab (Imfinzi) and Tremelimumab-actl (Imjudo)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-123 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Day RehabilitationPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA10-005 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Daratumumab (Darzalex), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-079 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Corneal Pachymetry Using UltrasoundPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA07-046 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Care Management and Care Planning ServicesPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA00-006 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Bioimpedance for the Detection of LymphedemaPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA07-052 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Atezolizumab (Tecentriq) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-127 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Aqueous Shunts, Minimally Invasive Glaucoma Surgeries (including Microstents), Viscocanalostomy, and Canaloplasty for the Treatment of GlaucomaPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA11-105 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Alemtuzumab (Lemtrada)PayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-015 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Acute Care Facility Inpatient TransfersPayerPolicy · AMERIHEALTH-MEDICARE-ADVANTAGE-MA12-003 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Ustekinumab for Intravenous InfusionPayerPolicy · AMERIHEALTH-COMMERCIAL-08-00-82 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Treatments for Complex Regional Pain Syndrome (CRPS)PayerPolicy · AMERIHEALTH-COMMERCIAL-08-00-57 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Tocilizumab and Related Biosimilars for Intravenous InfusionPayerPolicy · AMERIHEALTH-COMMERCIAL-08-00-85 | New policy |
|---|
| Sep 30, 2026 | AmeriHealth | Tildrakizumab-asmn (Ilumya)PayerPolicy · AMERIHEALTH-COMMERCIAL-08-01-48 | New policy |
|---|